Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cancer02:18

Cancer

51.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial.

JAMA network open·2026
Same author

Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation.

Trends in pharmacological sciences·2026
Same author

Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity.

Science advances·2026
Same author

Lymphotoxin-beta receptor controls the development of chronic pain.

Cell reports·2026
Same author

Rethinking ovarian cancer III: the past decade and future directions.

Nature reviews. Cancer·2026
Same author

Differential effects of SARS-CoV-2-targeted infection of ATII, club cells, and macrophages on lung immunopathology and antiviral responses.

Mucosal immunology·2026

Video Experimental Relacionado

Updated: May 5, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.2K

CD95 promueve el crecimiento tumoral.

Lina Chen1, Sun-Mi Park, Alexei V Tumanov

  • 1The Ben May Department for Cancer Research, The University of Chicago, 924 E 57th Street, Chicago, Illinois 60637, USA.

Nature
|May 28, 2010
PubMed
Resumen

La señalización del receptor CD95 (Fas), a menudo relacionada con la muerte celular, promueve sorprendentemente el crecimiento tumoral. Inhibir CD95, no potenciarlo, puede ser una estrategia viable para el tratamiento del cáncer.

Más Videos Relacionados

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K

Videos de Experimentos Relacionados

Last Updated: May 5, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.2K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K

Área de la Ciencia:

  • Inmunología Inmunología.
  • Biología del cáncer Biología del cáncer.
  • La señalización molecular.

Sus antecedentes:

  • El receptor CD95 (Fas) es crucial para la homeostasis del sistema inmunológico a través de la apoptosis.
  • Las células tumorales a menudo desregulan CD95 o resisten la apoptosis, lo que sugiere que la pérdida de CD95 ayuda a la evasión tumoral.
  • Paradójicamente, muchos cánceres expresan CD95 y su ligando (CD95L), lo que insinúa funciones no apoptóticas.

Objetivo del estudio:

  • Para investigar el papel de la señalización CD95 en el crecimiento tumoral.
  • Para determinar si CD95 promueve la tumorigénesis a través de vías no apoptóticas.
  • Evaluar el CD95 como un objetivo terapéutico en el cáncer.

Principales métodos:

  • Análisis de la expresión de CD95 y la sensibilidad a la apoptosis en las células cancerosas.
  • Investigando la señalización CD95 en modelos de ratón de cáncer de ovario y hígado.
  • Elucidando la vía de señalización aguas abajo (JNK/Jun) involucrada en la tumorigénesis mediada por CD95.

Principales resultados:

  • Las células cancerosas dependen de la actividad constitutiva de CD95, estimulada por CD95L producido por el cáncer, para el crecimiento.
  • La pérdida de CD95 redujo significativamente la incidencia del cáncer y el tamaño del tumor en modelos de ratón.
  • La promoción tumoral impulsada por CD95 involucra las vías de señalización JNK y Jun.

Conclusiones:

  • CD95 juega un papel pro-tumorigénico en el desarrollo y la progresión del cáncer.
  • Dirigirse a la actividad de CD95, en lugar de mejorarla, es una estrategia terapéutica prometedora.
  • Comprender las funciones no apoptóticas de CD95 es fundamental para desarrollar tratamientos efectivos contra el cáncer.